Sakar gets EU approval to make Imatinib for Accord UK, first of 9 oncology products

Regulatory product approvalExport order in hard currencyBusiness Updates View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹412.50

prior close

₹413.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%+1.0% vs market

Pharmaceuticals peers, median of 153sector+0.6%+1.7% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+1.5

15m

+1.8

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3+1.3+1.0+0.6+1.7

Next day

+2.3+2.6-0.3+1.3+1.0

+4.1+2.7+1.4+1.4+2.7

+2.9+2.1+0.8+1.4+1.5

+3.0+1.6+1.4+0.7+2.4

+0.8+0.8+0.0-0.0+0.9

-2.1+2.2-4.2+0.7-2.8

15d

-9.6-1.6-7.9-1.0-8.5

-2.5-3.0+0.5-1.8-0.7

+11.5-1.6+13.1-4.0+15.5

+28.1-10.5+38.6-10.2+38.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sakar Healthcare's oncology site in Ahmedabad has secured EU variation approval from EMA to manufacture Imatinib 100 mg and 400 mg tablets for Accord Healthcare UK, positioning the company to supply the European market. This is the first of 9 Accord oncology products planned to be manufactured at Sakar. The company expects a positive impact on top-line sales with improved capacity utilization. Sakar can now supply about a dozen approved products overseas.

Likely market impact

Positive for revenue and capacity use; opens EU market via Accord. First of 9 planned oncology transfers, signalling a growth pipeline.